CL2019002855A1 - Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. - Google Patents

Anticuerpos anti-ilt4 y fragmentos de unión a antígeno.

Info

Publication number
CL2019002855A1
CL2019002855A1 CL2019002855A CL2019002855A CL2019002855A1 CL 2019002855 A1 CL2019002855 A1 CL 2019002855A1 CL 2019002855 A CL2019002855 A CL 2019002855A CL 2019002855 A CL2019002855 A CL 2019002855A CL 2019002855 A1 CL2019002855 A1 CL 2019002855A1
Authority
CL
Chile
Prior art keywords
binding fragments
antigen
antibodies
ilt4 antibodies
ilt4
Prior art date
Application number
CL2019002855A
Other languages
English (en)
Inventor
Luis A Zuniga
Barbara Joyce-Shaikh
Milan Blanusa
Andrea Claudia Schuster
Kornelia Schultze
Original Assignee
Merck Sharp & Dohme
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Agenus Inc filed Critical Merck Sharp & Dohme
Publication of CL2019002855A1 publication Critical patent/CL2019002855A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS QUE SE UNEN A ILT4 (TRANSCRITO DE TIPO INMUNOGLOBULINA 4) Y COMBINACIONES DE LOS MISMOS, POR EJEMPLO, CON UN ANTICUERPO ANTI-PD1. TAMBIÉN SE PROPORCIONAN PROCEDIMIENTOS DE USO DE LOS MISMOS, POR EJEMPLO, PARA TRATAR O PREVENIR EL CÁNCER EN UN SUJETO; Y PROCEDIMIENTOS DE PREPARACIÓN DE DICHOS ANTICUERPOS Y FRAGMENTOS.
CL2019002855A 2017-04-07 2019-10-04 Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. CL2019002855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483019P 2017-04-07 2017-04-07

Publications (1)

Publication Number Publication Date
CL2019002855A1 true CL2019002855A1 (es) 2020-02-21

Family

ID=62063229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002855A CL2019002855A1 (es) 2017-04-07 2019-10-04 Anticuerpos anti-ilt4 y fragmentos de unión a antígeno.

Country Status (27)

Country Link
US (3) US11053315B2 (es)
EP (1) EP3606958A1 (es)
JP (2) JP7045392B2 (es)
KR (1) KR102357823B1 (es)
CN (1) CN110719917A (es)
AR (1) AR111362A1 (es)
AU (2) AU2018248294B2 (es)
BR (1) BR112019021000A2 (es)
CA (1) CA3057378A1 (es)
CL (1) CL2019002855A1 (es)
CO (1) CO2019011155A2 (es)
CR (1) CR20190459A (es)
DO (1) DOP2019000253A (es)
EA (1) EA201992402A1 (es)
EC (1) ECSP19072235A (es)
GE (1) GEP20227440B (es)
IL (1) IL269593A (es)
JO (1) JOP20190236B1 (es)
MX (1) MX2019011927A (es)
NI (1) NI201900103A (es)
PE (1) PE20191813A1 (es)
PH (1) PH12019502275A1 (es)
SG (1) SG11201909081YA (es)
TN (1) TN2019000272A1 (es)
TW (1) TWI796329B (es)
UA (1) UA126865C2 (es)
WO (1) WO2018187518A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
AR114002A1 (es) 2017-12-22 2020-07-08 Jounce Therapeutics Inc Anticuerpos a lilrb2
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
US20210301020A1 (en) * 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
EP3852805A4 (en) * 2018-09-17 2022-06-15 Icahn School of Medicine at Mount Sinai ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
CN114555637A (zh) 2019-08-12 2022-05-27 比昂生物制剂公司 针对ilt2的抗体及其用途
CN112442527B (zh) * 2019-08-27 2022-11-11 深圳市英马诺生物科技有限公司 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用
EP4076521A4 (en) * 2019-12-20 2024-01-24 Merck Sharp & Dohme LLC METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPY AGENTS
CA3166571A1 (en) * 2020-01-02 2021-07-08 Merck Sharp & Dohme Llc Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
KR20220137032A (ko) * 2020-02-05 2022-10-11 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 신규 lilrb2 항체 및 이의 용도
US11802155B2 (en) 2020-05-01 2023-10-31 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof
WO2022060767A1 (en) * 2020-09-17 2022-03-24 Merck Sharp & Dohme Corp. Dosing regimens of anti-ilt4 antibody or its combination with anti-pd-1 antibody for treating cancer
AU2022253269A1 (en) * 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
EP4380605A1 (en) 2021-08-05 2024-06-12 ImmunOs Therapeutics AG Combination medicaments comprising hla fusion proteins
BR112024002198A2 (pt) 2021-08-05 2024-04-30 Immunos Therapeutics Ag Composições farmacêuticas compreendendo proteínas de fusão do hla
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023114346A2 (en) * 2021-12-16 2023-06-22 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
WO2023192798A2 (en) * 2022-03-28 2023-10-05 Coherus Biosciences, Inc. Anti-ilt4 compositions and methods
WO2023211868A1 (en) * 2022-04-29 2023-11-02 Merck Sharp & Dohme Llc Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望（蘇州）生物醫藥科技有限公司 抗lilrb2抗體及其用途
WO2024022462A1 (zh) * 2022-07-29 2024-02-01 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
WO2024041315A1 (en) * 2022-08-22 2024-02-29 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-lilrb2 antibodies and uses thereof
WO2024051804A1 (zh) * 2022-09-08 2024-03-14 江苏恒瑞医药股份有限公司 抗ilt4抗体及其医药用途
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
DK2264177T3 (en) 1998-12-09 2016-01-11 Phyton Holdings Llc Glycoproteins with human-type glycosylation
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2412701A1 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
MXPA04004491A (es) 2001-11-14 2005-05-16 Immunex Corp Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide.
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
DE102004034416A1 (de) 2004-07-15 2006-02-02 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Flüssige, strahlunghärtende Zusammensetzungen
US7875278B2 (en) 2005-02-18 2011-01-25 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
CN101529255A (zh) 2006-11-14 2009-09-09 健泰科生物技术公司 神经元再生的调控剂
WO2012012716A2 (en) 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Targeting micrornas for the treatment of fibrosis
TW201247700A (en) 2011-05-05 2012-12-01 Baylor Res Inst Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
ES2770314T3 (es) 2011-12-30 2020-07-01 Cellscript Llc Fabricación y uso de ARN monocatenario sintetizado in vitro para introducción en células de mamífero para inducir un efecto biológico o bioquímico
WO2013181438A2 (en) 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
JP5858411B2 (ja) 2012-12-28 2016-02-10 国立大学法人大阪大学 コラーゲン結合性分子を付加した改変ラミニンおよびその利用
WO2014164519A1 (en) * 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
CN114457044A (zh) 2013-10-25 2022-05-10 普西奥克瑟斯医疗有限公司 武装有异源基因的溶瘤腺病毒
KR20170007449A (ko) 2014-05-22 2017-01-18 프레드 헛친슨 켄서 리서치 센터 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016044022A1 (en) 2014-09-16 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016218900A1 (en) 2015-02-11 2017-08-24 University Health Network Methods and compositions for modulating LILR proteins
KR102381948B1 (ko) * 2015-03-06 2022-04-01 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
EP3481400A4 (en) 2016-07-11 2020-04-01 Dana-Farber Cancer Institute, Inc. METHODS OF TREATING PTEN-DEFICIENT EPITHELIAL CANCERS USING A COMBINATION OF ANTI-PI3KBETA AND ANTI-CONTROL POINT AGENTS
WO2018022881A2 (en) 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
EP3344263A4 (en) 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIQUES AND USES THEREOF
JP2019524162A (ja) 2016-08-18 2019-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア モジュラーＡＡＶ送達システムによるＣＲＩＳＰＲ−Ｃａｓゲノム編集
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CA3038475A1 (en) 2016-09-28 2018-04-05 Immpact-Bio Ltd. A universal platform for car therapy targeting a novel antigenic signature of cancer
AR114002A1 (es) 2017-12-22 2020-07-08 Jounce Therapeutics Inc Anticuerpos a lilrb2
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體

Also Published As

Publication number Publication date
JP2020519235A (ja) 2020-07-02
BR112019021000A2 (pt) 2020-05-05
US20220002403A1 (en) 2022-01-06
UA126865C2 (uk) 2023-02-15
US20220033496A1 (en) 2022-02-03
MX2019011927A (es) 2020-02-10
TN2019000272A1 (en) 2021-01-07
AU2021225143A1 (en) 2021-09-30
US11897957B2 (en) 2024-02-13
NI201900103A (es) 2019-10-31
KR20190136064A (ko) 2019-12-09
JOP20190236A1 (ar) 2019-10-06
CA3057378A1 (en) 2018-10-11
EP3606958A1 (en) 2020-02-12
GEP20227440B (en) 2022-11-25
AU2018248294A1 (en) 2019-10-10
PE20191813A1 (es) 2019-12-26
SG11201909081YA (en) 2019-10-30
EA201992402A1 (ru) 2020-02-19
JP7394160B2 (ja) 2023-12-07
TWI796329B (zh) 2023-03-21
TW201839014A (zh) 2018-11-01
WO2018187518A1 (en) 2018-10-11
JOP20190236B1 (ar) 2023-09-17
US20180298096A1 (en) 2018-10-18
AU2018248294B2 (en) 2021-08-05
AR111362A1 (es) 2019-07-03
JP7045392B2 (ja) 2022-03-31
JP2022084773A (ja) 2022-06-07
PH12019502275A1 (en) 2020-09-21
US11897956B2 (en) 2024-02-13
CN110719917A (zh) 2020-01-21
ECSP19072235A (es) 2019-12-27
DOP2019000253A (es) 2019-12-15
IL269593A (en) 2019-11-28
US11053315B2 (en) 2021-07-06
CO2019011155A2 (es) 2019-10-21
CR20190459A (es) 2020-02-14
KR102357823B1 (ko) 2022-01-28

Similar Documents

Publication Publication Date Title
CL2019002855A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno.
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
BR112018012113A2 (pt) anticorpos monoclonais de ctla4 anti-humana quiméricos e humanizados e usos dos mesmo
ECSP19078414A (es) Anticuerpos anti-cd33 y métodos para utilizarlos
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
AR113757A1 (es) Anticuerpos anti-cd38 y métodos de uso
AR106996A1 (es) Anticuerpos monoclonales anti-ctla4 humano quiméricos y humanizados y sus usos
AR112401A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos
AR112758A1 (es) Anticuerpos agonistas que unen cd137 humano, y usos de los mismos
AR110569A1 (es) ANTICUERPOS MONOCLONALES ANTI-a-SINUCLEÍNA PARA PREVENIR LA AGREGACIÓN DE TAU
EA202090586A2 (ru) Триспецифичные связывающие молекулы и способы их применения
AR099899A1 (es) Anticuerpos y fragmentos anti-vista